doxorubicin

You have access
The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma
ELENA ORTONA, SILVIA L. LOCATELLI, MARIA TERESA PAGANO, BARBARA ASCIONE, GIUSEPPA CAREDDU, MARIA LUISA DUPUIS, MATTEO MARCONI, CARMELO CARLO-STELLA, WALTER MALORNI, PAOLA MATARRESE and MARINA PIERDOMINICI

Anticancer Research February 2022, 42 (2) 767-779; DOI: https://doi.org/10.21873/anticanres.15535
You have access
Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells
KATSUHITO NAGAI, SHUHEI FUKUNO, MAHO SHIOTA, MAYUKO TAMURA, SAYAKA YABUMOTO and HIROKI KONISHI

Anticancer Research December 2021, 41 (12) 6105-6112; DOI: https://doi.org/10.21873/anticanres.15430
You have access
Doxorubicin Combined With Ifosfamide for Sarcoma Induces Muscle Atrophy and Sleep Disruption
HIDEYUKI KINOSHITA, YOKO HAGIWARA, TAKESHI ISHII, HIROTO KAMODA, TOSHINORI TSUKANISHI, SEIJI OHTORI and TSUKASA YONEMOTO

Anticancer Research December 2021, 41 (12) 6273-6278; DOI: https://doi.org/10.21873/anticanres.15448
You have access
The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model
NATHANIEL F. WU, JUN YAMAMOTO, YUSUKE AOKI, NORIYUKI MASAKI, CARISSA SAMONTE, JUSTIN WU, MICHAEL BOUVET and ROBERT M. HOFFMAN

Anticancer Research October 2021, 41 (10) 4715-4718; DOI: https://doi.org/10.21873/anticanres.15285
You have access
Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient
HIDEKO AKAGI, AKIHIKO SHIMADA, KENKO CHIN and HIDEHARU DOMOTO

Anticancer Research June 2021, 41 (6) 3139-3144; DOI: https://doi.org/10.21873/anticanres.15099
You have access
Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells
DOROTA KOSTRZEWA-NOWAK and JOLANTA TARASIUK

Anticancer Research March 2021, 41 (3) 1429-1438; DOI: https://doi.org/10.21873/anticanres.14900
You have access
Novel TSPO-targeted Doxorubicin Prodrug for Colorectal Carcinoma Cells
JEMIANNE B. JIA, XIAOXI LING, MINZHI XING, JOHANNES M. LUDWIG, MINGFENG BAI and HYUN S. KIM

Anticancer Research October 2020, 40 (10) 5371-5378; DOI: https://doi.org/10.21873/anticanres.14545
You have access
Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin αII-Overexpressing Ovarian Carcinoma
OSAMU MAEDA, HIROAKI KAJIYAMA, KIYOSUMI SHIBATA, SHIGEO NAKAMURA and FUMITAKA KIKKAWA

Anticancer Research May 2020, 40 (5) 2497-2507; DOI: https://doi.org/10.21873/anticanres.14220
You have access
New Chalcone Derivative Inhibits ABCB1 in Multidrug Resistant T-cell Lymphoma and Colon Adenocarcinoma Cells
MARTINA ČIŽMÁRIKOVÁ, PETER TAKÁČ, GABRIELLA SPENGLER, ANNAMÁRIA KINCSES, MÁRTA NOVÉ, MÁRIA VILKOVÁ and JÁN MOJŽIŠ

Anticancer Research December 2019, 39 (12) 6499-6505; DOI: https://doi.org/10.21873/anticanres.13864
You have access
Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells
AZHAAR ALTURKISTANI, NISANNE GHONEM, VERNA-ANN POWER-CHARNITSKY, ALEJANDRO PINO-FIGUEROA and MATTIA M. MIGLIORE

Anticancer Research October 2019, 39 (10) 5297-5310; DOI: https://doi.org/10.21873/anticanres.13723

Main menu

User menu

Search

doxorubicin

Pages